Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Antje Walz"'
Publikováno v:
Inducing Targeted Protein Degradation. :313-336
Autor:
Kathryn Packman, Lyubomir Vassilev, David Heimbrook, Christophe Meille, Michael Linn, Rosario Garrido, Violeta Adames, Shahid Tannu, Kenneth Kolinsky, Edmund Lee, Sazzad Hussain, Zoran Filipovic, Christian Tovar, Antje Walz, Kelli Glenn, Brian Higgins
PDF file - 311KB, Table S1. Results of proliferation assay. Table S2. Estimated PKPD population parameters. Fig. S1. Schematic view of the PK/PD model. Fig S2. Observed PK parameter and model predicted. Fig S3. Visual predictive check.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03937509c03c999ff11b402c64c3a3e1
https://doi.org/10.1158/1078-0432.22456187
https://doi.org/10.1158/1078-0432.22456187
Autor:
Kathryn Packman, Lyubomir Vassilev, David Heimbrook, Christophe Meille, Michael Linn, Rosario Garrido, Violeta Adames, Shahid Tannu, Kenneth Kolinsky, Edmund Lee, Sazzad Hussain, Zoran Filipovic, Christian Tovar, Antje Walz, Kelli Glenn, Brian Higgins
Purpose: Antitumor clinical activity has been demonstrated for the MDM2 antagonist RG7112, but patient tolerability for the necessary daily dosing was poor. Here, utilizing RG7388, a second-generation nutlin with superior selectivity and potency, we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29b1e546610afd48a3c935087a456191
https://doi.org/10.1158/1078-0432.c.6523232.v1
https://doi.org/10.1158/1078-0432.c.6523232.v1
Autor:
Shengli Ding, Naveen R. Natesh, Kassandra Spiller, Rui Xi, Daniel Nelson, Nikolche Gjorevski, Antje Walz, Estelle Marrer-Berger, Hans Clevers, Shiaowen David Hsu, Xiling Shen
Publikováno v:
Journal of Clinical Oncology. 40:2573-2573
2573 Background: Current patient-derived organoid (PDO) models are largely devoid of immune components. We developed a precision microfluidic and membrane platform to generate patient-derived micro-organospheres (MOS) that retain tumor-resident immun
Autor:
Christophe Boetsch, Estelle Marrer Berger, Anneliese Schneider, Gabrielle Leclercq, Vesna Pulko, Antje Walz, Cristiano Ferlini, Christian Klein, Helene Haegel
Publikováno v:
Regular and young investigator award abstracts.
Background T cell bispecific antibodies (TCBs) are extremely potent T cell engagers, harboring a 2+1 format with one binder to the CD3e chain and two binders to specific tumor antigens. Crosslinking of CD3 with tumor antigens triggers T cell activati
Publikováno v:
Drug Discovery Today: Technologies. :27-34
In this review we present ways in which translational PK/PD modeling can address opportunities to enhance probability of success in drug discovery and early development. This is achieved by impacting efficacy and safety-driven attrition rates, throug
Publikováno v:
mAbs. 8:113-119
Biodistribution coefficients (BC) allow estimation of the tissue concentrations of proteins based on the plasma pharmacokinetics. We have previously established the BC values for monoclonal antibodies. Here, this concept is extended by development of
Autor:
Elina Pietilae, Thierry Lavé, Isabelle Walter, Adrian Roth, Stefan Kustermann, Nicole A. Kratochwil, Athanassios Iliadis, Christophe Meille, Antje Walz, Stephan Benay, P. Alexis Gonsard
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics. 42:275-285
Real time cell analysis (RTCA) is an impedance-based technology which tracks various living cell characteristics over time, such as their number, morphology or adhesion to the extra cellular matrix. However, there is no consensus about how RTCA data
Autor:
Michael Linn, Sazzad Hussain, Zoran Filipovic, Packman Kathryn E, Christophe Meille, Edmund J.D. Lee, Kenneth Kolinsky, David C. Heimbrook, Antje Walz, Lyubomir T. Vassilev, Brian Higgins, Rosario Garrido, Violeta Adames, Kelli Glenn, Christian Tovar, Shahid Tannu
Publikováno v:
Clinical Cancer Research. 20:3742-3752
Purpose: Antitumor clinical activity has been demonstrated for the MDM2 antagonist RG7112, but patient tolerability for the necessary daily dosing was poor. Here, utilizing RG7388, a second-generation nutlin with superior selectivity and potency, we
Autor:
Dominik Rüttinger, Florian Heil, Randolph Christen, Christophe Le Tourneau, Devalingam Mahalingam, Michael Brewster, Antje Walz, C. Willemien Menke-van der Houven van Oordt, Michael A. Cannarile, Tapan K. Nayak, Ernesto Guarin, Valerie Meresse, Henk M.W. Verheul, Winette T. A. van der Graaf, Carlos Gomez-Roca, Stefan Weigand, Carla M.L. van Herpen, Andrew L. Coveler
Publikováno v:
Menke, C W, Gomez-Roca, C, van Herpen, C, Coveler, A L, Mahalingam, D, Verheul, H M W, van der Graaf, W T A, Christen, R, Ruettinger, D, Weigand, S, Cannarile, M A, Heil, F, Brewster, M, Walz, A-C, Nayak, T K, Guarin, E, Meresse, V & Le Tourneau, C 2016, ' First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors ', Oncotarget, vol. 7, no. 48, pp. 80046-80058 . https://doi.org/10.18632/oncotarget.11098
Oncotarget
Oncotarget, 7(48), 80046-80058. Impact Journals
Oncotarget
Oncotarget, 7(48), 80046-80058. Impact Journals
// C. Willemien Menke-van der Houven van Oordt 1 , Carlos Gomez-Roca 2 , Carla van Herpen 3 , Andrew L. Coveler 4 , Devalingam Mahalingam 5 , Henk M. W. Verheul 1 , Winette T. A. van der Graaf 3 , Randolph Christen 6 , Dominik Ruttinger 7 , Stefan We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4e2b3d48416f0e6edb2768480044066
https://research.vumc.nl/en/publications/ccfdebc6-56b5-4554-85b2-67217b7dd862
https://research.vumc.nl/en/publications/ccfdebc6-56b5-4554-85b2-67217b7dd862